Musclepharm cannot expect much from investors being a highly dilutive public company. Musclepharm issues a ton of stocks each year to short term endorsements deals and to management and board members as stock grants that are vested over few years, while not being profitable at the same time. Not cool!
How could Musclepharm dilute the stock with 20% in 2014 when it didn't raise any capital but bought back stocks? it doesn't make any sense!
News 
Market Data 
Discover 
AI
